DEPARTMENT NAME
Department of Clinical Chemistry and Biochemistry

CONTACT DETAILS FOR HEAD OF DEPARTMENT
Prof. Ireneusz Majsterek, PhD
ireneusz.majsterek@umed.lodz.pl
+48 42 639 30 06

Department of Clinical Chemistry and Biochemistry
pl. Hallera 1
90-647 Lodz, Poland
www.zchbk.umed.pl

TEAM MEMBERS
Prof. Ireneusz Majsterek, PhD
Magda Cuchra, PhD
Ewa Gendek, PhD
Jacek Kabziński, PhD
Katarzyna Malinowska, PhD
Małgorzata Mrowicka, PhD
Bartosz Mucha, PhD
Alicja Nowak-Zduńczyk, PhD
Karolina Przybyłowska-Sygut, PhD
Anna Nowak, PhD
Dawid Budny, MSc
Lucjan Maciejczak, MSc
Jerzy Mrowicki, MSc Eng
Agnieszka Rogalska, MSc

SHORT DESCRIPTION OF RESEARCH ACTIVITY
The Department uses modern molecular biology techniques (Western blot, real-time PCR, apoptosis, cell cycle progression, cytotoxicity, DNA damage and repair) as well as a number of self-designed authorial tests including the comet, BER, NER and HRR assays. In addition, cell cultures are performed using various cell lines. Research areas include the molecular basis of neurodegenerative disorders such as Alzheimer’s disease, POAG, MS, and various types of cancer.

DEPARTMENTAL ACHIEVEMENTS: PROJECTS AND PAPERS

Publications:

1. Pytel D, Gao Y, i wsp.. PERK Is a Haploinsufficient Tumor Suppressor: Gene Dose Determines Tumor-Suppressive Versus Tumor Promoting Properties of PERK in Melanoma. PLoS Genet 2016
2. Pytel D, Majsterek I, Diehl JA: Tumor progression and the different faces of the PERK kinase. Oncogene
3. Cuchra M, Mucha B, Markiewicz Ł, et al.: The role of base excision repair In pathogenesis of Brest cancer In the Polish population. Molecular Carcinogenesis 2015. Projects:
4. “Inhibitors of ER stress-dependent PERK kinase as a novel approach for Alzheimer’s therapy”, NCN no. 2013/10/M/NZ1/00280
5. “New opportunities for use of PERK kinase inhibitors in eIF2alfa factor-dependent signalling pathway in antitumortherapy”, NCN no. 2015/19/N/NZ3/00055
6. “Development of electromagnetic heating technology for nano-ferroelectric ferromagnetics for selective thermocell neoplasia”, NCBR no. PBS2/A5/31/2013